A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers

AIDS

Volumn 19, Issue 12, 2005, Pages 1289-1297

  Gray, Glenda E ^a,c   Urban, Michael ^b   Chersich, Matthew F ^a   Bolton, Carolyn ^a   Van Niekerk, Ronelle ^a   Violari, Avy ^a   Stevens, Wendy ^a   McIntyre, James A ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Africa; Breastfeeding; Infant HIV 1 infection; Mother to child transmission; Nevirapine; Postexposure prophylaxis; Zidovudine

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; BREAST FEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RISK; JAUNDICE; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MALE; MENINGITIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEWBORN SEPSIS; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 24044498054     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000180100.42770.a7     Document Type: Article

References (38)

1. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries. Translating research into policy and practice. JAMA 2000; 283:1175-1182.
2. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. Six-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mere-Enfant. Lancet 1999; 353:786-792.
3. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-785.
4. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-1186.
5. Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
6. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
7. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child HIV transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343:982-991.
8. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
9. World Health Organization. Antiretroviral Drugs and the Prevention of Mother-to-Child Transmission of HIV Infection in Resource-limited Settings: Expert Consultation. Geneva: World Health Organization; February, 2004. Online: http://www.who.int/3by5/arv_pmtct/en/ (accessed 18 June 2004).
10. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000; 355:2237-2244.
11. Centers for Disease Control and Prevention. Case-controlled study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 1995; 44:929-933.
12. Shih CC, Kaneshima H, Rabin L, Namikawa R, Sager P, McGowan J, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991; 163:625-627.
13. van Rompay KK, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992; 36:2381-2386.
14. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
15. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362:1171-1177.
16. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-1414.
17. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002; 4:59-63.
18. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, et al. Characterization of nevirapine resistance mutations in women with subtype A vs D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-130.
19. Sullivan J, for the South African Intrapartum Nevirapine Trial (SAINT) Study Team. Selection of resistant mutations. XIV International Conference on AIDS. Barcelona, July 2002 [abstract LbPeB902].
20. Martinson N, Morris L, Gray G, Moodley D, Lupondwana P, Chezzi C, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT Cohort. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 38].
21. Kantor R, Lee E, Johnston E, Mateta P, Zijenah L, Maldonado Y, et al., for the HPTN 023 Team. Rapid flux in non-nuceleoside reverse transcriptase inhibitor resistance mutations among subtype C HIV-1 infected women after single dose nevirapine. 2003; Antiviral Therapy 8:S85.
22. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al., for the Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
23. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
24. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. j Infect Dis 1998; 178:368-374.
25. Duarte G., Mussi-Pinhata M.M., Cervi M.C., Kato C.M., Paschoini M.C., Quintana S.M. Can isolated postpartum zidovudine prophylaxis reduce perinatal HIV transmission? World Conference of Gynaecology and Obstetrics. Washington DC, September 2000 [abstract P4.12.01, XVI FIGO].
26. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275:640-641.
27. Boyer PJ, Dillon M, Navaie M, Deveikis A, Keller M, O'Rourke S, et al. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994; 271:1925-1930.
28. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer VVA III, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatrie AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-393.
29. Leroy V, Karon JM, Alioum A, Ekpini ER, Meda N, Greenberg AE, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002; 16:631-641.
30. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-1174.
31. Moodley D, Moodley J, Coovadia H, Cray C, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-735.
32. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999; 354:803-809.
33. Dabis F, Ekpini E. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002:359.
34. Bassett MT. Ensuring a public health impact of programs to reduce HIV transmission from mothers to infants: the place of voluntary counseling and testing. Am J Public Health 2002; 92:347-351.
35. Steinbrook R. Beyond Barcelona: the global response to HIV. N Engl J Med 2002; 347:553-554.
36. Stringer JS, Rouse DJ, Sinkala M, Marseille EA, Vermund SH, Stringer EM, et al. Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus. Lancet 2003; 362:1850-1853.
37. Chersich M, Violari A, Jivkov B, Urban M, Gray G. Initiating early postpartum voluntary counselling and testing (PP-VCT) in resource-constrained settings. XIV International Conference on AIDS. Barcelona, July 2002 [abstract TuPeF5398].
38. Pillay CCN, Gray G, Chezzi C, Ntsala M, Stevens G, Stevens W, et al. Nevirapine resistance mutations among HIV-1 infected infants following single dose nevirapine. XV International Conference on AIDS. Bangkok, July 2004 [abstract WeOrB1290].